YD Bio Limited begins trading on Nasdaq under YDES, YDESW symbols.

YD Bio Limited has completed its business combination with Breeze Holdings Acquisition Corp, positioning the biotech company for accelerated innovation and market expansion. Trading of the company's common stock and warrants is expected to commence on the Nasdaq Global Market on August 29, 2025, under the ticker symbols "YDES" and "YDESW." The transaction was approved by Breeze shareholders at an extraordinary general meeting held on August 14, 2025.

YD Bio Limited, a biotechnology company focused on DNA methylation-based cancer detection and ophthalmologic innovations, has successfully completed its business combination with Breeze Holdings Acquisition Corp. The company is set to commence trading on the Nasdaq Global Market on August 29, 2025, under the ticker symbols "YDES" and "YDESW" [1].

The transaction, which was approved by Breeze shareholders at an extraordinary general meeting held on August 14, 2025, positions YD Bio Limited for accelerated innovation and market expansion. The company has secured over $11.5 million in funding through a PIPE offering and trust proceeds, which will be used to fund future operations [1].

YD Bio Limited's core programs include a proprietary DNA methylation-based detection technology for a range of cancers, including a screening test for early detection of pancreatic cancer and a monitoring test for recurrent breast cancer. The company is also advancing corneal stem cell and exosome technologies for the treatment of ocular diseases such as dry eye syndrome, glaucoma, and corneal injury. Additionally, YD Bio Limited provides clinical trial support services to global pharmaceutical companies [1].

The company's business model centers on partnerships with biopharmaceutical companies to transform innovative technologies into commercially viable drugs and cancer detection diagnostics. Led by Chairman Dr. Ethan Shen, a biomedical expert with over 30 years of experience, YD Bio Limited is focused on advancing a diversified portfolio of innovative healthcare solutions across oncology diagnostics, regenerative medicine, and clinical trial support [1].

While the $11.5 million raised through the PIPE offering and trust proceeds may appear modest for a biotech company with multiple development programs, the company's business model of partnerships and licensing agreements may help mitigate capital requirements. The leadership of Chairman Dr. Ethan Shen adds credibility to the company's strategic direction in navigating the complex biotech landscape and partnership opportunities ahead [2].

References:
[1] https://finance.yahoo.com/news/yd-bio-limited-announces-closing-183300354.html
[2] https://www.stocktitan.net/news/YDES/yd-bio-limited-announces-closing-of-business-combination-and-listing-8ljcqne4wcp2.html